Multiple Sclerosis: Where Will We Be in 2020?

被引:18
|
作者
Miller, Aaron E. [1 ]
机构
[1] Mt Sinai Sch Med, New York, NY USA
来源
MOUNT SINAI JOURNAL OF MEDICINE | 2011年 / 78卷 / 02期
关键词
genetics; immunology; MS; multiple sclerosis; therapeutics; PLACEBO-CONTROLLED TRIAL; EPSTEIN-BARR-VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DOUBLE-BLIND; ORAL FINGOLIMOD; MULTICENTER; RISK; DISABILITY; INTERFERON-BETA-1A; NATALIZUMAB;
D O I
10.1002/msj.20242
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The past decade has seen a surge of research interest in multiple sclerosis and an accelerated expansion of investigative efforts into multiple sclerosis therapeutics. Investigators have continued dissecting the complex immunological perturbations that may contribute to the disease and made major advances in understanding the genetics of multiple sclerosis. This article addresses current investigative issues and offers predictions about where the understanding and treatment of multiple sclerosis may stand at the end of the 21st century's second decade. Mt Sinai J Med 78:268-279, 2011. (C) 2011 Mount Sinai School of Medicine
引用
收藏
页码:268 / 279
页数:12
相关论文
共 50 条
  • [21] Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies
    Healy, Brian
    Chitnis, Tanuja
    Engler, David
    JOURNAL OF NEUROLOGY, 2011, 258 (10) : 1812 - 1819
  • [22] LSN MS guidelines for the management of multiple sclerosis
    Shatila, A. R.
    Koussa, S.
    Jabbour, R.
    Mourad, A.
    Aouad, A.
    Sabbagh, G.
    Kallab, K.
    Hilal, R.
    Khalifeh, R.
    Gebeily, S.
    Tourbah, A.
    REVUE NEUROLOGIQUE, 2013, 169 (12) : 950 - 955
  • [23] Principles of a new treatment algorithm in multiple sclerosis
    Hartung, Hans-Peter
    Montalban, Xavier
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Olsson, Tomas
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (03) : 351 - 362
  • [24] Remyelination in multiple sclerosis: what do we know and where are we going?
    Williams, Anna
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (01) : 49 - 59
  • [25] Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
    Boziki, Marina Kleopatra
    Kesidou, Evangelia
    Theotokis, Paschalis
    Mentis, Alexios-Fotios A.
    Karafoulidou, Eleni
    Melnikov, Mikhail
    Sviridova, Anastasia
    Rogovski, Vladimir
    Boyko, Alexey
    Grigoriadis, Nikolaos
    BRAIN SCIENCES, 2020, 10 (04)
  • [26] Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?
    Wasnik, Samiksha
    Sharma, Isha
    Baylink, David J.
    Tang, Xiaolei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [27] AI in Radiology: Where are we today in Multiple Sclerosis Imaging?
    Eichinger, Paul
    Zimmer, Claus
    Wiestler, Benedikt
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2020, 192 (09): : 847 - 853
  • [28] Progressive multiple sclerosis
    Ontaneda, Daniel
    Fox, Robert J.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (03) : 237 - 243
  • [29] Review of methodological issues of clinical trials in multiple sclerosis
    Montalban, Xavier
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 : S35 - S42
  • [30] The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement
    Moiola, Lucia
    Barcella, Valeria
    Benatti, Simone
    Capobianco, Marco
    Capra, Ruggero
    Cinque, Paola
    Comi, Giancarlo
    Fasolo, Maria Michela
    Franzetti, Fabio
    Galli, Massimo
    Gerevini, Simonetta
    Meroni, Luca
    Origoni, Massimo
    Prosperini, Luca
    Puoti, Massimo
    Scarpazza, Cristina
    Tortorella, Carla
    Zaffaroni, Mauro
    Riva, Agostino
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 331 - 346